{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:51:01Z","timestamp":1792605061428,"version":"4.5.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      We observed an increase in the frequency of\n                      <jats:italic>Candida auris<\/jats:italic>\n                      among invasive candidiasis isolates in the 2022 SENTRY Antifungal Surveillance Program compared to prior years: \u22640.1% before 2018, 0.4%\u20130.6% from 2018 to 2021, and 1.6% in 2022.\n                      <jats:italic>C. auris<\/jats:italic>\n                      isolates were collected in seven countries, but 28 (35.9%) isolates were recovered in the USA (five states; more common in New York, Texas, and New Jersey) and 26 (33.3%) in Panama. Greece and Turkey had 12 and 9 isolates, respectively. Overall, 82.1% of the isolates were resistant to fluconazole; 17.9% were resistant to amphotericin B; and 1.3% were resistant to caspofungin, anidulafungin, or micafungin (Centers for Disease Control and Prevention tentative resistance breakpoints). Rezafungin inhibited 96.2% of the isolates (Clinical and Laboratory Standards Institute susceptibility breakpoint). Pandrug resistance was not observed, but 17.9% of the isolates were resistant to fluconazole and amphotericin B. South Asian (Clade I) isolates were most common (\n                      <jats:italic>n<\/jats:italic>\n                      = 40, 51.3%); of these, 97.5% were resistant to fluconazole and 30.0% were resistant to amphotericin B. Thirty (38.5%) isolates belonged to the South American region (Clade IV), and 56.7% of those were resistant to fluconazole and 6.7% to amphotericin B. Seven isolates belonged to the South African Clade III and one to East Asian Clade II. Erg11 (Y132F, K143R, and F126L) and MRR1 (N647T) alterations were detected. One isolate that was resistant to all echinocandins carried an FKS R1354G alteration. Two isolates displayed elevated rezafungin minimum inhibitory concentration (MIC) values but low MIC values against other echinocandins and no FKS alterations. As\n                      <jats:italic>C. auris<\/jats:italic>\n                      is spreading globally, monitoring this species is prudent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00570-24","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T09:05:29Z","timestamp":1726131929000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":38,"title":["Recent increase in\n                    <i>Candida auris<\/i>\n                    frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-1132","authenticated-orcid":true,"given":"Lalitagauri M.","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[{"name":"Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03364-19"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw691"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2008.00083.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01624-18"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03081"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00808-21"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6544e1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2019.05.008"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01588-17"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2125349"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2017.127"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-012-9551-x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01686-12"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-20"},{"key":"e_1_3_2_16_2","volume-title":"Performance standards for antifungal susceptibility testing of yeasts","author":"CLSI","year":"2022","unstructured":"CLSI. 2022. M27 M44S. In Performance standards for antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_2_17_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. M27. In Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"4"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01584-23"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01427-18"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00067-22"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03333-20"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00365-20"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02663-20"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00029-17"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.578"},{"key":"e_1_3_2_26_2","unstructured":"WHO. 2022. WHO fungal priority pathogens list to guide research development and public health action. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240060241"},{"key":"e_1_3_2_27_2","unstructured":"CDC. 2023. Increasing threat of spread of antimicrobial-resistant fungus in healthcare facilities. Available from: https:\/\/www.cdc.gov\/media\/releases\/2023\/p0320-cauris.html#:~:text=CDC%20has%20deemed%20C. infections%20with%20high%20death%20rates"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200846"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3469"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05543-0"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01519-13"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2016.07.003"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.021"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2022.102208"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00057-19"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01445"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof9050529"},{"key":"e_1_3_2_38_2","unstructured":"CDC. 2023. About Candida auris (C. auris). Available from: https:\/\/www.cdc.gov\/fungal\/candida-auris\/candida-auris-qanda.html#:~:text=C.%20auris%20is%20often%20resistant of%20antifungal%20medicines%20called%20echinocandins"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01572-18"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky153"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00570-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00570-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:47:42Z","timestamp":1728388062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00570-24"}},"subtitle":[],"editor":[{"given":"Damian J.","family":"Krysan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,8]]}},"alternative-id":["10.1128\/aac.00570-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00570-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"2024-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00570-24"}}